163 related articles for article (PubMed ID: 37343829)
1. Relatlimab-nivolumab: A practical overview for dermatologists.
Mullick N; Nambudiri VE
J Am Acad Dermatol; 2023 Nov; 89(5):1031-1037. PubMed ID: 37343829
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
Phillips AL; Reeves DJ
Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
[TBL] [Abstract][Full Text] [Related]
4. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.
Su J; Fu Y; Cui Z; Abidin Z; Yuan J; Zhang X; Li R; Zhao C
Front Pharmacol; 2023; 14():1349081. PubMed ID: 38269271
[TBL] [Abstract][Full Text] [Related]
5. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab and relatlimab for the treatment of melanoma.
Chen XY; Li YD; Xie Y; Cao LQ; Ashby CR; Zhao H; Chen ZS
Drugs Today (Barc); 2023 Feb; 59(2):91-104. PubMed ID: 36811409
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab Plus Relatlimab: First Approval.
Paik J
Drugs; 2022 Jun; 82(8):925-931. PubMed ID: 35543970
[TBL] [Abstract][Full Text] [Related]
8. Complete Remission of Metastatic Melanoma of the Scalp Following Treatment With Nivolumab Plus Relatlimab.
McMinn ME; Brister KA; Orr WS; Sheehan NT; Christopher WO
Am Surg; 2024 Mar; ():31348241241642. PubMed ID: 38553440
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.
Thudium K; Selby M; Zorn JA; Rak G; Wang XT; Bunch RT; Hogan JM; Strop P; Korman AJ
Cancer Immunol Res; 2022 Oct; 10(10):1175-1189. PubMed ID: 35981087
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA; Lipson EJ; Dummer R; Larkin J; Long GV; Sanborn RE; Chiarion-Sileni V; Dréno B; Dalle S; Schadendorf D; Callahan MK; Nyakas M; Atkinson V; Gomez-Roca CA; Yamazaki N; Tawbi HA; Sarkis N; Warad D; Dolfi S; Mitra P; Suryawanshi S; Grob JJ
J Clin Oncol; 2023 May; 41(15):2724-2735. PubMed ID: 36780608
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
Koseła-Paterczyk H; Rutkowski P
Expert Opin Biol Ther; 2023 May; 23(5):383-388. PubMed ID: 37200112
[TBL] [Abstract][Full Text] [Related]
12. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
Albrecht LJ; Livingstone E; Zimmer L; Schadendorf D
Curr Oncol Rep; 2023 Jun; 25(6):647-657. PubMed ID: 37004702
[TBL] [Abstract][Full Text] [Related]
13. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
Hegewisch-Becker S; Mendez G; Chao J; Nemecek R; Feeney K; Van Cutsem E; Al-Batran SE; Mansoor W; Maisey N; Pazo Cid R; Burge M; Perez-Callejo D; Hipkin RW; Mukherjee S; Lei M; Tang H; Suryawanshi S; Kelly RJ; Tebbutt NC
J Clin Oncol; 2024 May; ():JCO2301636. PubMed ID: 38723227
[TBL] [Abstract][Full Text] [Related]
14. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
15. Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
Zhao Y; Hu Z; Bathena SP; Keidel S; Miller-Moslin K; Statkevich P; Bello A; Roy A; Suryawanshi S
Clin Cancer Res; 2024 Jan; ():. PubMed ID: 38295151
[TBL] [Abstract][Full Text] [Related]
16. Abscopal effect observed in visceral and osseous metastases after liver SBRT in combination with nivolumab and relatlimab for sinonasal mucosal melanoma-a case report.
Cerbon D; Moya-Brown K; Mihaylov IB; Spieler B
Front Oncol; 2023; 13():1143335. PubMed ID: 37182135
[TBL] [Abstract][Full Text] [Related]
17. Advancement of anti-LAG-3 in cancer therapy.
Li Y; Ju M; Miao Y; Zhao L; Xing L; Wei M
FASEB J; 2023 Nov; 37(11):e23236. PubMed ID: 37846808
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN; Postow M; Burton EM; Tetzlaff MT; Ross MI; Torres-Cabala C; Glitza IC; Duan F; Milton DR; Busam K; Simpson L; McQuade JL; Wong MK; Gershenwald JE; Lee JE; Goepfert RP; Keung EZ; Fisher SB; Betof-Warner A; Shoushtari AN; Callahan M; Coit D; Bartlett EK; Bello D; Momtaz P; Nicholas C; Gu A; Zhang X; Korivi BR; Patnana M; Patel SP; Diab A; Lucci A; Prieto VG; Davies MA; Allison JP; Sharma P; Wargo JA; Ariyan C; Tawbi HA
Nature; 2022 Nov; 611(7934):155-160. PubMed ID: 36289334
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
Schuler M; Cuppens K; Plönes T; Wiesweg M; Du Pont B; Hegedus B; Köster J; Mairinger F; Darwiche K; Paschen A; Maes B; Vanbockrijck M; Lähnemann D; Zhao F; Hautzel H; Theegarten D; Hartemink K; Reis H; Baas P; Schramm A; Aigner C
Nat Med; 2024 Apr; ():. PubMed ID: 38689060
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.
Ossato A; Damuzzo V; Baldo P; Mengato D; Chiumente M; Messori A
Cancer Med; 2023 Feb; 12(3):2155-2165. PubMed ID: 35920297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
